Circulatory Support Failed to Lower Heart Event Risks
A new meta-analysis found mechanical support devices provided no 30-day benefit for high-risk patients undergoing heart procedures.
Updated on Sept. 22, 2026 in Heart Disease
Live Poll
Do you trust that common medical support interventions during high-risk surgery always improve patient outcomes?
Researchers determined that prophylactic mechanical circulatory support does not reduce major adverse cardiovascular events (MACE) in high-risk patients undergoing percutaneous coronary intervention. The findings suggest no device strategy significantly lowered the risk for such events compared to standard care at the 30-day mark.
Why it matters
The study clarifies the role of advanced circulatory support tools in high-risk cardiology, showing they do not provide the anticipated clinical protection against major cardiovascular outcomes. This assessment helps clinicians weigh the use of expensive, invasive interventions against conventional care protocols.
The meta-analysis of 1,856 patients, with a mean age of 66, included 727 receiving percutaneous LVAD and 512 receiving IABP. While overall MACE risk showed no improvement, percutaneous LVAD and IABP did reduce periprocedural major adverse events.
The details
Investigators compared the outcomes of three device strategies—percutaneous LVAD, IABP, and VA-ECMO—against a control group of 344 patients who received standard care. Although the devices did not improve 30-day MACE outcomes, the data indicated a reduced risk for periprocedural major adverse events.
Timeline
September 9, 2026: Study findings published online.
30 days: Follow-up period for MACE risk assessment.
10.8 months: Mean follow-up duration for MACE, stroke, and MI.
14.1 months: Mean follow-up duration for death risk.
The Big Picture
This research updates clinical practice by clarifying the lack of prophylactic benefit for specific device strategies within current guidelines for percutaneous coronary intervention.
This news indicates that high-risk patients may not necessarily see a benefit from additional prophylactic circulatory devices during routine interventions. Patients should discuss the specific risks and advantages of these mechanical support options with their cardiologists.
The takeaway
Clinicians must balance the usage of advanced support devices against the evidence of their limited impact on long-term major cardiovascular outcomes. This highlights the necessity of relying on comparative clinical trial data rather than assumptions regarding device efficacy for high-risk patients.
Further reading
Find more comprehensive research on cardiovascular care in our Heart Disease section.
Source note: This article includes information reported by Medscape.
Live Poll
Do you trust that common medical support interventions during high-risk surgery always improve patient outcomes?
